Skip to content

The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children

The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children : A Single Center ,Randomized ,Double-blinded, Controlled Study.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02222636
Enrollment
60
Registered
2014-08-21
Start date
2014-09-30
Completion date
2015-12-31
Last updated
2014-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Efficacy and Safety of Intranasal Dexmedetomidine

Keywords

The efficacy and safety of intranasal dexmedetomidine

Brief summary

The purpose of this study is to explore the optimal protocol for dexmedetomidine used in children during perioperative period.

Interventions

DRUGNormal saline,1 milliliter

Normal saline,1 milliliter, 20 minutes before anaesthetic induction

DRUGDexmedetomidine 1 μg.kg-1,1 milliliter

Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction

DRUGDexmedetomidine 2μg.kg-1,1 milliliter

Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction

DRUGAnesthesia induction, 8% sevoflurane

Inhalation induction with 8% sevoflurane

DRUGAnesthesia maintenance, 2%~3% sevoflurane,fentanyl

2%\ 3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Months to 7 Years
Healthy volunteers
No

Inclusion criteria

* Written informed consent. * Elective cleft lip and cleft palate repair surgery * American Society of Anesthesiologists class I * Aged between 6 months and 7 years old

Exclusion criteria

* Suspected or confirmed difficult airway * History of upper respiratory tract infection with 1 month * Combined with congenital heart disease * Allergic to investigational products or with other contraindication * Growth retardation or dysgnosia * Central nervous system disease * Serious infection * Serious heart,brain,liver,kidney, pulmonary, and endocrine disease

Design outcomes

Primary

MeasureTime frame
Change from baseline in respiratory rate during anesthesiaThe moment of entering operating room,20 minutes before anesthesia induction,10 minutes before anesthesia inducion,the moment of anesthesia induction
Sedation-Agitation ScaleThe moment of entering operating room,20 minutes before anesthesia induction,10 minutes before anesthesia inducion,the moment of anesthesia induction
The pediatric anesthesia emergence delirium scaleThe moment of entering operating room,and from discontinuation of inhalational anesthetics to the moment of patient's consciousness recovery,an expected average of 1 hour
Anesthesia induction timeFrom beginning of inhalating anesthetics to the moment of intubation
Anesthesia maintenance timeFrom the moment of intubation to the discontinuation of inhalational anesthestics
Recovery timeFrom discontinuation of inhalational anesthestics to the moment of patient's consciousness recovery, an expected average of 1 hour
Change from baseline in blood pressure during anesthesiaThe moment of entering operating room,20 minutes before anesthesia induction,10 minutes before anesthesia inducion,the moment of anesthesia induction
Change from baseline in heart rate during anesthesiaThe moment of entering operating room,20 minutes before anesthesia induction,10 minutes before anesthesia inducion,the moment of anesthesia induction

Secondary

MeasureTime frame
The alveolar concentration of inhalational anestheticsthe moment of anesthesia induction,the moment of intubation,before cutting skin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026